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OBJECTIVES: Estimate potential direct savings for the Mexican Healthcare System
generated by the operation of the Technical Guidelines for distribution of food and
beverages in establishments of basic education targeting population of 6 to 14
years of age. METHODS: The authors use the micro-simulation model Chronic
Disease Prevention (CDP) developed by the OECD-WHO for projecting health gains
and costs of treatment in a period of 100 years. The model was adjusted to accom-
modate the range of ages stated in the Guidelines and uses information of inci-
dence, prevalence, mortality, population at risk, annual unit costs and relative risk
of selected chronic diseases (diabetes mellitus type 2, hypertension, cardio- and
cerebro-vascular, hypercholesterolemia) attributable to obesity as well as the treat-
ment of obesity as disease itself for the Mexican context. Sensitivity analyses were
developed for most variables used in the model. RESULTS: Under the base case
scenario present value of potential savings in total spending on medical care asso-
ciated with the implementation of the Guidelines amount to USD$1,052.2 million in
2008. Most savings are derived from averted cases of hypertension (32.7%), obesity-
overweight (28.6%) and diabetes mellitus type II (17.8%). Results are robust to
changes in all parameters analyzed. Amounts obtained are an underestimation of
potential savings as neither expensive complications as renal failure nor other
chronic diseases attributable to obesity as arthritis, colorectal or breast cancer were
included. CONCLUSIONS: The Guidelines, developed by both Ministry of Public
Education and Ministry of Health, represent a good example of cooperation among
different sectors to solve a complex public health problem. Results shows the impor-
tance of implementing preventive interventions aimed at reducing the prevalence of
chronic diseases related to poor eating habits, inadequate physical activity and obesity
in Mexico. The implementation of the Guidelines involves significant direct savings
that can be assigned to other health needs of the Mexican population.
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OBJECTIVES: To describe the resource utilization and the costs related to heavy
menstrual bleeding (HMB) control with either an LNG-IUS or hysterectomy in the
Brazilian Public Health System (SUS) on patients treated at the Department of
Obstetrics and Gynecology, School of Medical Sciences, University of Campinas,
Brazil. METHODS: We performed an observational retrospective descriptive study
with costs evaluation and budgetary impact calculation from data extracted from
medical files of patients diagnosed with HMB treated either with the LNG-IUS or
hysterectomy. The measured outcomes were HMB control, LNG-IUS induced com-
plications (expulsion, uterine perforation, pelvic inflammatory disease), LNG-IUS
continuation rate and hospital costs after one year, as well as, the budgetary im-
pact of the use of LNG-IUS in the treatment of HMB vs. hysterectomy. RESULTS:
Two hundred sixty-seven medical files were initially retrieved for analysis. A total
of 246 patients were included in this study, 122 received the LNG-IUS and 124 were
treated with hysterectomy. The mean age was 39.7 years in the LNG-IUS group and
47.9 in the surgery group. Mean duration of HMB in the hysterectomy group was 3.2
years, twice that of the LNG-IUS group (1.5 years) (p0.01). Of the patients treated
with LNG-IUS, 88.7% maintained the device for over one year and 83.1% had suc-
cess in bleeding control with this method. Fourteen patients had to have the LNG-
IUS removed prior to 12 months; however, only 1.6% because of failure in bleeding
control. Costs for the LNG-IUS insertion in a one-year time horizon were R$ 762.64
versus R$ 870.03 for the hysterectomy procedure. CONCLUSIONS: When applied to
the eligible population in SUS the budgetary impact of the LNG-IUS adoption was
an economy of almost R$ 3.6 million.
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OBJECTIVOS: Establecer la Costo-efectividad de levonorgestrel-UIS (LNG-UIS) en el
tratamiento de Menorragia Idiopática comparado con otras opciones de trata-
miento (Anticonceptivo Oral Combinado, Acido Tranexámico, Acido Mefenámico y
Naproxeno). METODOLOGÍAS: Se realizo un análisis de costo-efectividad desde la
perspectiva del tercero pagador evaluando como desenlace el tiempo libre de sin-
tomatologías ganado y el número de histerectomías evitadas. Las probabilidades
de transición fueron obtenidas de estudios clínicos. Se tomaron los costos directos
de atención a precios del 2010. No se incluyó la Ablación endometrial por no ser de
uso en Colombia Se aplico un descuento del 3% anual para costos y desenlaces. Se
realizó un análisis de sensibilidad tipo Montecarlo con 2000 iteraciones y un análi-
sis univariado tipo tornado. RESULTADOS: Para una cohorte hipotética de 100
mujeres y un horizonte temporal de 5 años el costo del brazo con LNG-UIS fue de
100,993 USD frente a 116,726 USD, 127,513 USD, 103,497 y 125,330 USD (Anticoncep-
tivo Oral Combinado, Acido Tranexámico, Acido Mefenámico y Naproxeno respec-
tivamente). Con LNG-UIS se lograron 5.413 meses sin sintomatología frente a 5.110,
4.975, 5.028 y 4791 respectivamente. Con LNG-UIS se evitaron, 77 Histerectomías
frente a 58, 74,75 Y 65 respectivamente. LNG-UIS fue dominante frente a los demás
comparadores para los desenlaces analizados. El análisis de sensibilidad tipo Mon-
tecarlo mantuvo dominancia del LNG-UIS en más del 99%. CONCLUSIONES: El uso
de LNG-UIS como primera opción de tratamiento en mujeres con menorragia id-
iopática es la mejor alternativa por cuanto es menos costoso y más efectiva desde
la perspectiva del tercero pagador en Colombia.
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OBJECTIVES: To predict the cost-effectiveness of vaccination with measles,
mumps, rubella, and varicella (MMRV) vs MMR in Mexico. METHODS: A dynamic
mathematical model was used to reproduce the age-related incidence of varicella
and zoster. The impact of introducing varicella vaccination was predicted at pop-
ulation-level including costs and quality of life. Empirical age-specific contact rates
between individuals were used. Vaccine efficacy against varicella was assumed to
be 95% after two doses (1y and 6y). We assessed the impact of vaccination in a
base-case (coverage dose1: 90%; dose2: 80%) and in an optimal scenario (higher
coverage dose1:95%; dose2:90% and catch-up programme); and the cost-effective-
ness of replacing MMR with MMRV using 5% discount rates for benefits and costs.
RESULTS: In the long-term, MMRV vaccination is predicted to result in a 90%
decrease in varicella incidence (with short-term epidemics due to rebound effect)
and a90% decrease in zoster cases (with a temporary increase due to the assump-
tion on exogenous boosting). At 1, 5, 30, and 80 years, MMRV versus MMR is pre-
dicted to result in: - more QALYs saved (31, 209, 925, and 1306); - more complica-
tions avoided (2, 6, 132, 1864); and - less deaths (0.15, 1.09, 8.39, 28.95). Despite
increased vaccine costs vs MMR, MMRV was cost saving at all time points in terms
of GP/outpatient, hospital, indirect, and total ($7.9, $56.5, $226.9, and $331.2 million,
respectively) costs. Cost-effectiveness planes for direct and total costs indicate that
MMRV would provide more QALYs than MMR, and is cost saving. These results are
for the base-case scenario. For optimal scenario, results were similar or even better.
CONCLUSIONS: MMRV vaccination should result in significant reduction in vari-
cella and zoster cases in the long-term. We predict the replacement of MMR by
MMRV to be dominant under both scenarios.
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OBJECTIVES: Chronic infection with hepatitis C virus (HCV) is a major and growing
public health concern in many, if not all, Latin American countries. With more
efficacious therapies becoming available, decision-makers require accurate esti-
mates of disease prevalence to assess the cost-benefit ratio of new treatments for
HCV infection. These estimates are challenging to derive because HCV infection
often remains asymptomatic – and therefore undetected – until the liver has been
seriously damaged. The objective of the study was to synthesize estimates of the
epidemiologic burden of HCV from Latin America. METHODS: A systematic review
was conducted in Medline and EMBASE by two reviewers to identify population-
based estimates of HCV prevalence from Argentina, Brazil, Colombia, Mexico, Peru,
and Venezuela since 2000. Studies were only included if they were considered
methodologically adequate, and randomly sampled representative members of the
general population. Counts and rates of positive HCV tests from national blood
bank networks were also synthesized. RESULTS: Only one methodologically ade-
quate Latin American population-based survey, from Mexico, was identified; the
estimated HCV prevalence was 1.4% (1.1%-1.6%). Estimates of HCV prevalence
among blood donors were: 0.66% (Argentina, 2008), 0.53% (Brazil, 2007), 0.57% (Co-
lombia, 2006), 0.66% (Mexico, 2007), 0.81% (Peru, 2007), and 0.37% (Venezuela, 2005).
CONCLUSIONS: Based on the review, Mexico is the only Latin American country
with robust estimates of HCV prevalence; the potential societal burden is enor-
mous as about 1.5% of the population is infected. Rates from blood donors under-
estimate true HCV prevalence; and the differences between population-based and
blood donor estimates for Mexico help frame the extent of that underestimate.
These population-based prevalence estimates, and the prevalence estimates from
blood donors, may be useful for inclusion in disease models. Discrepancies be-
tween estimates from the different sources underscore the need for methodolog-
ically-rigorous epidemiologic studies to maximally inform decision-makers in
Latin America.
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FACING CRITICAL HEALTH EVENTS: ECONOMIC IMPACT OF AH1N1 FLU
EPIDEMIC IN THE MEXICAN HEALTH SECTOR, 2009-2010
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